Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells

Bindu Noolu1, Rajanna Ajumeera, Anitha Chauhan

  • 1Department of Endocrinology & Metabolism, National Institute of Nutrition, Hyderabad, India.

Abstract

Insights

Curry leaves extract (CLE) inhibits the 26S proteasome, a key protein-degrading machine, leading to cancer cell death. This natural compound shows potential as a novel cancer therapy agent.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The 26S proteasome's proteolytic activity is a promising target for cancer therapy.
  • Polyphenols and flavonoids are known to inhibit proteasome activity.
  • Murraya koenigii (curry leaves) is a rich source of polyphenols with traditional medicinal uses.

Purpose of the Study:

  • To investigate the effect of Murraya koenigii leaves extract on 26S proteasome activity.
  • To determine if curry leaf extract induces cancer cell death.
  • To explore the potential of curry leaves as a source for anti-cancer agents.

Main Methods:

  • Preparation of hydro-methanolic extract of curry leaves (CLE).
  • Assessment of cytotoxicity using MTT assay on breast cancer cell lines (MCF-7, MDA-MB-231) and normal fibroblasts (WI-38).
  • Analysis of cell cycle, apoptosis (Annexin-V binding), and 26S proteasome activity in treated cells.

Main Results:

  • CLE decreased viability and altered growth kinetics in breast cancer cells dose-dependently.
  • CLE induced S-phase arrest and apoptosis in cancer cells.
  • CLE significantly inhibited 26S proteasome activity in cancer cells but not in normal cells.

Conclusions:

  • Murraya koenigii leaves are a potent source of proteasome inhibitors.
  • CLE induces cancer cell death through proteasome inhibition and apoptosis.
  • Active components from curry leaves may lead to novel anti-cancer drug development.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...